A subset of patients recruited in the main MATRIX study will be randomized after intervention but before discharge to standard of care (the treating physician will decide which oral P2Y12 inhibitor will be added on top of aspirin) versus a customized approach based on an algorithm which integrates phenotypic information, including but not limited to residual on-treatment platelet reactivity assessed via VerifyNow P2Y12 Assay.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Cardiovascular death, myocardial infarction, stroke or BARC defined bleeding type 2, 3 or 5
Timeframe: 1 year
Proportion of patients in the therapeutic range for residual P2Y12 pathway activity according to PRU values.
Timeframe: 30 days